Purple Biotech Ltd Stock Price, News & Analysis

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on oncology therapeutics, has closed its previously announced public offering. The offering includes 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, with each ADS representing 200 ordinary shares, at $1.00 per share.

The offering also includes short-term warrants to purchase up to 11,999,998 ADSs at an exercise price of $1.00 per ADS, exercisable immediately and expiring in 24 months. The initial gross proceeds total $6 million, with potential additional proceeds of $12 million if all warrants are exercised. H.C. Wainwright & Co. served as the exclusive placement agent.

The company plans to use the proceeds for developing its oncology therapeutic candidates and general working capital purposes.

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor treatment, has announced the pricing of a $6 million public offering with potential additional proceeds of up to $12 million through warrant exercises.

The offering consists of 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, priced at $1.00 per share. Each ADS represents 200 ordinary shares. Additionally, short-term warrants to purchase up to 11,999,998 ADSs at $1.00 per ADS will be issued, exercisable immediately and expiring in 24 months. The offering is expected to close around September 5, 2025.

H.C. Wainwright & Co. serves as the exclusive placement agent. Proceeds will fund oncology therapeutic candidates development and general corporate purposes.

Purple Biotech (NASDAQ/TASE: PPBT) has announced promising new data for its CAPTN-3 tri-specific antibody IM1240 in collaboration with Mount Sinai. The research, led by Dr. Amir Horowitz, demonstrated successful tumor cell death in treatment-resistant head and neck cancer biopsies.

Key findings show synergistic effects between NK and T cell engager arms of IM1240, and analysis of 26,000 human transcriptomes validates the antibody's design targeting 5T4 and NKG2A. The company plans to submit an IND application in 2026 for first-in-human clinical trials.

The research spans multiple resistant cancers including NSCLC, HNSCC, and bladder cancer. IM1240's unique design offers potentially safer checkpoint inhibition compared to existing therapies, particularly through its selective NKG2A targeting.

Purple Biotech (NASDAQ/TASE: PPBT) has announced the development of IM1305, its second CAPTN-3 tri-specific antibody targeting TROP2. The novel antibody combines a masked anti-CD3 arm, an anti-NKG2A arm, and an anti-TROP2 arm to target solid tumors.

Preclinical results show sustained tumor regression in human triple negative breast cancer (TNBC) mouse models, with significant cell death induction across multiple tumor types at low doses. The antibody's unique design includes a cleavable cap that activates specifically in the tumor microenvironment, potentially reducing off-target effects.

TROP2, the target protein, is widely expressed in major solid tumors including breast, lung, gastrointestinal, and ovarian cancers. The company plans to leverage its platform technology to accelerate development and explore partnering opportunities.

Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

CEO Gil Efron will participate in a fireside chat on September 10, 2025, at 11:30 AM ET. The company will also be available for one-on-one investor meetings through the conference portal.

Purple Biotech (NASDAQ/TASE: PPBT) reported Q2 2025 financial results and significant clinical progress across its pipeline. The company highlighted positive data from its CAPTN-3 tri-specific antibody platform at EACR 2025, with plans to submit an IND for IM1240 in 2026.

Key clinical achievements include statistically significant Phase 2 results for CM24 in pancreatic cancer, showing up to 78% reduction in death risk and 37.5% ORR in biomarker-selected patients. The company also initiated a Phase 2 study of NT219 in head and neck cancer.

Financial highlights include reduced R&D expenses to $0.6M (down 76.9% YoY), operating loss of $1.2M (down 64.3% YoY), and cash position of $5.6M, providing runway into Q3 2026.

Purple Biotech (NASDAQ/TASE: PPBT) CEO Gil Efron shared significant progress in their clinical pipeline during H1 2025. The company's lead candidate CM24 showed promising Phase 2 results in pancreatic cancer (PDAC), with notably higher objective response rates in biomarker-enriched subgroups (37.5% vs 0% control).

Key developments include positive data from the CAPTN-3 platform presented at EACR 2025, featuring novel capping technology, and advancement of NT219 into Phase 2 combination studies. The company plans to initiate a biomarker-driven Phase 2b study for CM24 and expects to submit an IND for CAPTN-3's first candidate in 2026.

Purple Biotech maintains a cash runway extending into mid-2026, though additional funding will be required for future clinical studies.

Purple Biotech (NASDAQ/TASE: PPBT) presented new preclinical data on its CAPTN-3 tri-specific antibody platform at EACR 2025. The platform creates antibodies that safely activate both innate and adaptive immune systems to fight cancer. The lead product, IM1240, features a conditional anti-CD3 arm that activates only in tumor environments, an anti-NKG2A arm that engages NK cells and blocks immune checkpoints, and a tumor-targeting arm. Key data showed sustained tumor regression in triple negative breast cancer models, selective activation in tumor microenvironment, and synergistic effects between NK and T cell engagement. The platform demonstrated superior efficacy compared to individual antibodies and showed flexibility with other candidates like IM1060 and IM1065 also achieving significant tumor regression.

Purple Biotech (NASDAQ/TASE: PPBT) has initiated a Phase 2 clinical study of NT219 for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The study, conducted at the University of Colorado Anschutz Medical Campus, will evaluate NT219 in combination with either pembrolizumab or cetuximab. NT219 is a novel small molecule targeting IRS1/2 and STAT3 pathways. The trial consists of two single-arm cohorts, each starting with 10 patients and potentially expanding to 29 patients. The initiation follows encouraging Phase 1 results showing safety and anti-tumor activity, with two partial responses and five stable disease cases. The SCCHN treatment market is projected to reach $5 billion by 2030.